drugset / Trial / NCT00412932
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This 14 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients 65 years of age or older with high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.
Timeline
- Start
- 2006-12
- Primary completion
- 2008-04
- Completion
- 2008-04
Outcome
Met primary endpoint
registry MEAN Overall Study: -25.7 (Standard Error 0.96) mm Hg NCT00412932 ↗
registry analysis (superiority or other test); Overall Study; p <0.0001; one-sample t-test; note: No multiplicity adjustments NCT00412932 ↗
Publications
- Germino FW, Neutel JM, Dubiel R, Maa JF, Chavanu KJ. Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension. Am J Cardiovasc Drugs. 2012 Oct 1;12(5):325-33. doi: 10.1007/BF03261841.
- Neutel J, Kereiakes DJ, Stoakes KA, Maa JF, Shojaee A, Waverczak WF. Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age >/=65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study. Drugs Aging. 2011 Jun 1;28(6):477-90. doi: 10.2165/11589460-000000000-00000.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydrochlorothiazide | Unknown | 25 mg | — |
| Subject | Olmesartan medoxomil | Unknown | 40 mg | — |